Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial myxedema: A Case Series.

CONCLUSIONS: Immunomodulation therapy was followed by PTM improvement or stability in most patients, with slightly better response after rituximab as compared to IVIg. A validated response assessment instrument and larger series of patients are required to determine if the underlying disease process could be curtailed with these agents. PMID: 30854936 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research